"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Patients should be warned that at the first appearance of a skin rash they should stop use of DARAPRIM (pyrimethamine) and seek medical attention immediately. Patients should also be warned that the appearance of sore throat, pallor, purpura, or glossitis may be early indications of serious disorders which require treatment with DARAPRIM (pyrimethamine) to be stopped and medical treatment to be sought.
Women of childbearing potential who are taking DARAPRIM (pyrimethamine) should be warned against becoming pregnant. Patients should be warned to keep DARAPRIM (pyrimethamine) out of the reach of children. Patients should be advised not to exceed recommended doses. Patients should be warned that if anorexia and vomiting occur, they may be minimized by taking the drug with meals.
Last reviewed on RxList: 1/20/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Daraprim Information
Daraprim - User Reviews
Daraprim User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.